Holding(s) in Company

Arix Bioscience PLC (ARIX) Holding(s) in Company 17-Jul-2023 / 15:00 GMT/BST TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BD045071 Issuer Name ARIX BIOSCIENCE PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details of person subject to the notification obligation Name Ruffer LLP City of registered office (if applicable) London Country of registered office (if applicable) United Kingdom 4. Details of the shareholder Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above City of registered office (if applicable) Country of registered office (if applicable) 5. Date on which the threshold was crossed or reached 14-Jul-2023 6. Date on which Issuer notified 17-Jul-2023 7. Total positions of person(s) subject to the notification obligation . % of voting rights attached to shares (total of 8.A) % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) Total of both in % (8.A + 8.B) Total number of voting rights held in issuer Resulting situation on the date on which threshold was crossed or reached 4.977220 0.000000 4.977220 6440000 Position of previous notification (if applicable) 8. Notified details of the resulting situation on the date on which the threshold was crossed or reached 8A. Voting rights attached to shares Class/Type of shares ISIN code(if possible) Number of direct voting rights (DTR5.1) Number of indirect voting rights (DTR5.2.1) % of direct voting rights (DTR5.1) % of indirect voting rights (DTR5.2.1) GB00BD045071 6440000 0 4.977220 0.000000 Sub Total 8.A 6440000 4.977220% 8B1. Financial Instruments according to (DTR5.3.1R.(1) (a)) Type of financial instrument Expiration date Exercise/conversion period Number of voting rights that may be acquired if the instrument is exercised/converted % of voting rights Sub Total 8.B1 8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b)) Type of financial instrument Expiration date Exercise/conversion period Physical or cash settlement Number of voting rights % of voting rights Sub Total 8.B2 9. Information in relation to the person subject to the notification obligation 1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer. Ultimate controlling person Name of controlled undertaking % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold 10. In case of proxy voting Name of the proxy holder The number and % of voting rights held The date until which the voting rights will be held 11. Additional Information Ruffer LLP now controls the voting rights over 6,440,000 shares (less than 5% of the voting rights) of Arix Bioscience plc which are held by the discretionary clients of Ruffer LLP and its subsidiaries (the voting of which is all controlled by Ruffer LLP). This change from 5% to less than 5% is due to the sale of 80,000 shares by Ruffer LLP on 14 July 2023. 12. Date of Completion 17-Jul-2023 13. Place Of Completion Ruffer LLP Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

ISIN:	GB00BD045071
Category Code:	HOL
TIDM:	ARIX
LEI Code:	213800OVT3AHQCXNIX43
OAM Categories:	2.3. Major shareholding notifications
Sequence No.:	258222
EQS News ID:	1681769

End of Announcement	EQS News Service